Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Conference Call & Webcast Conference Call & Webcast Date:  Friday, November 3, 2023 Time:  8:30 a.m. ET Dial-In – North American Toll-Free:(888) 664-6383 Dial-In – International:  (416) 764-8650 RapidConnect:  to join the conference call without operator assistance, pleaseclick here Conference ID(if needed) :6026-0546 Webcast:  pleaseclick here A webcast of the call will also be available on the Investor Relations page of Oncolytics' website,...
Comunicato Precedente

next
Comunicato Successivo

next
Preferisci Informazione.News su Google

Conference Call & Webcast

Date: Friday, November 3, 2023

Time: 8:30 a.m. ET

Dial-In – North American Toll-Free: (888) 664-6383

Dial-In – International: (416) 764-8650

RapidConnect: to join the conference call without operator assistance, please click here

Conference ID (if needed): 6026-0546

Webcast: please click here

A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 390-0541 (North America) or (416) 764-8677 (International) and using replay code: 260-546#.

About Oncolytics Biotech Inc.

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in Phase 2 studies in breast and pancreatic cancers. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer. For further information, please visit: www.oncolyticsbiotech.com.

Director of IR & Communication

+1-858-886-7813

jpatton@oncolytics.ca 

LifeSci Advisors

+1-917-679-9282

tim@lifesciadvisors.com 

Logo: https://mma.prnewswire.com/media/1808285/4295352/Oncolytics_Biotech_Grey.jpg 

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-third-quarter-financial-results-and-recent-operational-highlights-301962805.html

Ufficio Stampa

 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom

Allegati
Slide ShowSlide Show
Non disponibili
;